Point72 Asia Singapore Pte. Ltd. Makes New $64,000 Investment in Artivion, Inc. (NYSE:AORT)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in Artivion, Inc. (NYSE:AORT) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,251 shares of the company’s stock, valued at approximately $64,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AORT. Smartleaf Asset Management LLC raised its position in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares in the last quarter. R Squared Ltd acquired a new position in shares of Artivion in the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new position in shares of Artivion during the 4th quarter worth approximately $43,000. Venturi Wealth Management LLC acquired a new stake in Artivion in the 4th quarter valued at $78,000. Finally, KBC Group NV grew its position in Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock valued at $80,000 after acquiring an additional 1,254 shares during the period. 86.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Stifel Nicolaus reduced their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $31.40.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the transaction, the chief executive officer now owns 663,882 shares of the company’s stock, valued at $18,130,617.42. This represents a 5.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. This represents a 3.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 101,347 shares of company stock worth $2,663,486 in the last quarter. Insiders own 7.60% of the company’s stock.

Artivion Stock Up 1.7%

Shares of NYSE AORT opened at $29.46 on Monday. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $32.33. The firm’s 50-day simple moving average is $24.64 and its 200 day simple moving average is $27.31. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -1,473.00 and a beta of 1.54.

Artivion (NYSE:AORT) last announced its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. On average, research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.